Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 10/20 | 0.77 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.60 |
| ▸ | HRH1 | P35367 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | FPR2 | P25090 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5772286 | 0.87 | HRH4 (1.00) | HRH4HRH3KMT2AHRH1MEN1 | |
| SCHEMBL2166664 | 0.87 | HRH4 (1.00) | HRH4HRH3KMT2AHRH1MEN1 | |
| SCHEMBL16598621 | 0.84 | HRH4 (0.75) | HRH4HRH3KMT2AHRH1MEN1 | |
| SCHEMBL5772717 | 0.84 | HRH4 (0.77) | HRH4HRH3KMT2AHRH1MEN1 | |
| SCHEMBL5775848 | 0.83 | HRH4 (0.76) | HRH4HRH3KMT2AHRH1MEN1 | |
| SCHEMBL13815897 | 0.83 | HRH4 (0.76) | HRH4HRH3KMT2AHRH1MEN1 | |
| SCHEMBL5775764 | 0.82 | HRH4 (0.84) | HRH4HRH3EHMT2 | |
| SCHEMBL16598664 | 0.81 | HRH4 (0.62) | HRH4HRH3KMT2AHRH1MEN1 | |
| SCHEMBL17938630 | 0.78 | HRH4 (0.86) | HRH4HRH3KMT2AHRH1MEN1 | |
| SCHEMBL5773436 | 0.77 | HRH4 (0.82) | HRH4HRH3HRH1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1671972-A1 | Octahydropyrrolo[3,4-c]pyrrole derivatives | Pfizer Limited (GB) | 2006-06-21 | — | — | EP | claimed |
| EP-1671972-A1 | Octahydropyrrolo[3,4-c]pyrrole derivatives | Pfizer Limited (GB) | 2006-06-21 | — | — | EP | disclosed |
| US-20060111416-A1 | Octahydropyrrolo[3,4-C]pyrrole derivatives | PFIZER INC. | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111416-A1 | Octahydropyrrolo[3,4-C]pyrrole derivatives | DPYD, PAH, DHPS | HRH4 1986/4885HRH3 3821/4885KMT2A 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.